Cancer Cachexia Market Report by Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others), Mode of Action (Appetite Stimulators, Weight Loss Stabilizers), Distribution Channel (Hospital Stores, Retail Pharmacy, Online Pharmacy), and R

The global cancer cachexia market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.9% during 2025-2033. The market is driven by the rising global cancer incidence, the growing recognition of cachexia's significant impact on patient outcomes, and increased research into targeted therapies, all of which aim to enhance patient quality of life and treatment effectiveness.

Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.

Cancer Cachexia Market Trends:

The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on therapeutics, mode of action, distribution channel.

Breakup by Therapeutics:

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

Breakup by Mode of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

Breakup by Distribution Channel:

• Hospital Stores
• Retail Pharmacy
• Online Pharmacy

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.

Key Questions Answered in This Report

1.What was the size of the global cancer cachexia market in 2024?

2.What is the expected growth rate of the global cancer cachexia market during 2025-2033?

3.What are the key factors driving the global cancer cachexia market?

4.What has been the impact of COVID-19 on the global cancer cachexia market?

5.What is the breakup of the global cancer cachexia market based on the therapeutics?

6.What is the breakup of the global cancer cachexia market based on the mode of action?

7.What are the key regions in the global cancer cachexia market?

8.Who are the key players/companies in the global cancer cachexia market?